Long-Term Treatment With Finasteride Results in a Clinically Significant Reduction in Total Prostate Volume Compared to Placebo Over the Full Range of Baseline Prostate Sizes in Men Enrolled in the MTOPS Trial

Steven A. Kaplan, Claus Roehrborn, John D. McConnell, Alan G. Meehan, Shailaja Surynawanshi, Jeannette Y. Lee, Jennifer Rotonda, John W. Kusek, Leroy M. Nyberg

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Purpose: In the present analysis we examined data from the MTOPS (Medical Therapy of Prostatic Symptoms) trial to determine the effect of long-term finasteride treatment, either alone or in combination with doxazosin, on total prostate volume across the full range of baseline total prostate volume values in men enrolled in this study. Materials and Methods: In this trial a total of 3,047 patients with lower urinary tract symptoms were randomized to placebo, doxazosin (4 to 8 mg), finasteride (5 mg) or the combination of doxazosin and finasteride (average length of treatment 4.5 years). Total prostate volume was measured by transrectal ultrasound in all patients at baseline, yearly and at study end or at termination of participation. Results: Long-term treatment with finasteride led to a consistent reduction of approximately 25% in total prostate volume compared to placebo in men with a relatively small prostate (less than 25 to 30 ml), as well as in those with a moderate size (30 to less than 40 ml) or enlarged prostate (40 ml or greater) at baseline. Conclusions: In this MTOPS data analysis long-term (more than 4 years) treatment with finasteride, either alone or in combination with doxazosin, led to a consistent, clinically significant reduction in total prostate volume compared to placebo in patients with lower urinary tract symptoms and benign prostatic hyperplasia whose baseline prostate size ranged from relatively small (less than 25 to 30 ml) to enlarged (40 ml or greater).

Original languageEnglish (US)
Pages (from-to)1030-1033
Number of pages4
JournalJournal of Urology
Volume180
Issue number3
DOIs
StatePublished - Sep 2008

Fingerprint

Finasteride
Prostate
Placebos
Doxazosin
Lower Urinary Tract Symptoms
Therapeutics
Prostatic Hyperplasia

Keywords

  • combined modality therapy
  • doxazosin
  • finasteride
  • prostatic hyperplasia
  • urinary tract

ASJC Scopus subject areas

  • Urology

Cite this

Long-Term Treatment With Finasteride Results in a Clinically Significant Reduction in Total Prostate Volume Compared to Placebo Over the Full Range of Baseline Prostate Sizes in Men Enrolled in the MTOPS Trial. / Kaplan, Steven A.; Roehrborn, Claus; McConnell, John D.; Meehan, Alan G.; Surynawanshi, Shailaja; Lee, Jeannette Y.; Rotonda, Jennifer; Kusek, John W.; Nyberg, Leroy M.

In: Journal of Urology, Vol. 180, No. 3, 09.2008, p. 1030-1033.

Research output: Contribution to journalArticle

Kaplan, Steven A. ; Roehrborn, Claus ; McConnell, John D. ; Meehan, Alan G. ; Surynawanshi, Shailaja ; Lee, Jeannette Y. ; Rotonda, Jennifer ; Kusek, John W. ; Nyberg, Leroy M. / Long-Term Treatment With Finasteride Results in a Clinically Significant Reduction in Total Prostate Volume Compared to Placebo Over the Full Range of Baseline Prostate Sizes in Men Enrolled in the MTOPS Trial. In: Journal of Urology. 2008 ; Vol. 180, No. 3. pp. 1030-1033.
@article{b0af13466b654e9eac22b684bcf7a371,
title = "Long-Term Treatment With Finasteride Results in a Clinically Significant Reduction in Total Prostate Volume Compared to Placebo Over the Full Range of Baseline Prostate Sizes in Men Enrolled in the MTOPS Trial",
abstract = "Purpose: In the present analysis we examined data from the MTOPS (Medical Therapy of Prostatic Symptoms) trial to determine the effect of long-term finasteride treatment, either alone or in combination with doxazosin, on total prostate volume across the full range of baseline total prostate volume values in men enrolled in this study. Materials and Methods: In this trial a total of 3,047 patients with lower urinary tract symptoms were randomized to placebo, doxazosin (4 to 8 mg), finasteride (5 mg) or the combination of doxazosin and finasteride (average length of treatment 4.5 years). Total prostate volume was measured by transrectal ultrasound in all patients at baseline, yearly and at study end or at termination of participation. Results: Long-term treatment with finasteride led to a consistent reduction of approximately 25{\%} in total prostate volume compared to placebo in men with a relatively small prostate (less than 25 to 30 ml), as well as in those with a moderate size (30 to less than 40 ml) or enlarged prostate (40 ml or greater) at baseline. Conclusions: In this MTOPS data analysis long-term (more than 4 years) treatment with finasteride, either alone or in combination with doxazosin, led to a consistent, clinically significant reduction in total prostate volume compared to placebo in patients with lower urinary tract symptoms and benign prostatic hyperplasia whose baseline prostate size ranged from relatively small (less than 25 to 30 ml) to enlarged (40 ml or greater).",
keywords = "combined modality therapy, doxazosin, finasteride, prostatic hyperplasia, urinary tract",
author = "Kaplan, {Steven A.} and Claus Roehrborn and McConnell, {John D.} and Meehan, {Alan G.} and Shailaja Surynawanshi and Lee, {Jeannette Y.} and Jennifer Rotonda and Kusek, {John W.} and Nyberg, {Leroy M.}",
year = "2008",
month = "9",
doi = "10.1016/j.juro.2008.05.004",
language = "English (US)",
volume = "180",
pages = "1030--1033",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Long-Term Treatment With Finasteride Results in a Clinically Significant Reduction in Total Prostate Volume Compared to Placebo Over the Full Range of Baseline Prostate Sizes in Men Enrolled in the MTOPS Trial

AU - Kaplan, Steven A.

AU - Roehrborn, Claus

AU - McConnell, John D.

AU - Meehan, Alan G.

AU - Surynawanshi, Shailaja

AU - Lee, Jeannette Y.

AU - Rotonda, Jennifer

AU - Kusek, John W.

AU - Nyberg, Leroy M.

PY - 2008/9

Y1 - 2008/9

N2 - Purpose: In the present analysis we examined data from the MTOPS (Medical Therapy of Prostatic Symptoms) trial to determine the effect of long-term finasteride treatment, either alone or in combination with doxazosin, on total prostate volume across the full range of baseline total prostate volume values in men enrolled in this study. Materials and Methods: In this trial a total of 3,047 patients with lower urinary tract symptoms were randomized to placebo, doxazosin (4 to 8 mg), finasteride (5 mg) or the combination of doxazosin and finasteride (average length of treatment 4.5 years). Total prostate volume was measured by transrectal ultrasound in all patients at baseline, yearly and at study end or at termination of participation. Results: Long-term treatment with finasteride led to a consistent reduction of approximately 25% in total prostate volume compared to placebo in men with a relatively small prostate (less than 25 to 30 ml), as well as in those with a moderate size (30 to less than 40 ml) or enlarged prostate (40 ml or greater) at baseline. Conclusions: In this MTOPS data analysis long-term (more than 4 years) treatment with finasteride, either alone or in combination with doxazosin, led to a consistent, clinically significant reduction in total prostate volume compared to placebo in patients with lower urinary tract symptoms and benign prostatic hyperplasia whose baseline prostate size ranged from relatively small (less than 25 to 30 ml) to enlarged (40 ml or greater).

AB - Purpose: In the present analysis we examined data from the MTOPS (Medical Therapy of Prostatic Symptoms) trial to determine the effect of long-term finasteride treatment, either alone or in combination with doxazosin, on total prostate volume across the full range of baseline total prostate volume values in men enrolled in this study. Materials and Methods: In this trial a total of 3,047 patients with lower urinary tract symptoms were randomized to placebo, doxazosin (4 to 8 mg), finasteride (5 mg) or the combination of doxazosin and finasteride (average length of treatment 4.5 years). Total prostate volume was measured by transrectal ultrasound in all patients at baseline, yearly and at study end or at termination of participation. Results: Long-term treatment with finasteride led to a consistent reduction of approximately 25% in total prostate volume compared to placebo in men with a relatively small prostate (less than 25 to 30 ml), as well as in those with a moderate size (30 to less than 40 ml) or enlarged prostate (40 ml or greater) at baseline. Conclusions: In this MTOPS data analysis long-term (more than 4 years) treatment with finasteride, either alone or in combination with doxazosin, led to a consistent, clinically significant reduction in total prostate volume compared to placebo in patients with lower urinary tract symptoms and benign prostatic hyperplasia whose baseline prostate size ranged from relatively small (less than 25 to 30 ml) to enlarged (40 ml or greater).

KW - combined modality therapy

KW - doxazosin

KW - finasteride

KW - prostatic hyperplasia

KW - urinary tract

UR - http://www.scopus.com/inward/record.url?scp=48649099681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48649099681&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2008.05.004

DO - 10.1016/j.juro.2008.05.004

M3 - Article

C2 - 18639298

AN - SCOPUS:48649099681

VL - 180

SP - 1030

EP - 1033

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 3

ER -